This Medical Letter review compares a newly approved 2-dose hepatitis B virus vaccine that uses a synthetic oligonucleotide immunostimulatory adjuvant, and is licensed for use in adults, with other commercially available 3-dose vaccines.
JAMA – American Medical Association
Published: Feb 27, 2018
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud